The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice

Critical Care Medicine

Volumn 37, Issue 2, 2009, Pages 614-618

  Stegenga, Michiel E ^a,b   Florquin, Sandrine ^c   De Vos, Alex F ^a,b   Van Der Poll, Tom ^a,b  

^a Center for Infection and Immunity Amsterdam CINIMA   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Ciglitazone; Diabetes mellitus type 2; Mice; Natural immunity; Pneumonia; Sepsis

Indexed keywords

CIGLITAZONE; CYTOKINE; MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL OVERGROWTH; C57BL MOUSE; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME BLOOD LEVEL; EXPERIMENTAL INFECTION; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG HOMOGENATE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; COLONY COUNT, MICROBIAL; CYTOKINES; FEMALE; HYPOGLYCEMIC AGENTS; INFLAMMATION; LUNG; MICE; MICE, INBRED C57BL; PEROXIDASE; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; THIAZOLIDINEDIONES;

EID: 67650349113     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819599b6     Document Type: Article

References (28)

1. Marrie TJ: Community-acquired pneumonia. Clin Infect Dis 1994; 18:501-513
2. Shah BR, Hux JE: Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26:510-513
3. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004; 351:1106-1118
4. Miyazaki Y, Mahankali A, Matsuda M, et al: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87:2784-2791
5. Reddy RC, Keshamouni VG, Jaigirdar SH, et al: Deactivation of murine alveolar macro-phages by peroxisome proliferator-activated receptor-gamma ligands. Am J Physiol Lung Cell Mol Physiol 2004; 286:L613-L619
6. Standiford TJ, Keshamouni VG, Reddy RC: Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2005; 2:226-231
7. Liu D, Zeng BX, Zhang SH, et al: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res 2005; 54: 464-470
8. Mueller C, Weaver V, Vanden Heuvel JP, et al: Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys 2003; 418:186-196
9. Woerly G, Honda K, Loyens M, et al: Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 2003; 198:411-421
10. Brown PD, Lerner SA: Community-acquired pneumonia. Lancet 1998; 352:1295-1302
11. Knapp S, Wieland CW, van 't Veer C, et al: Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 2004; 172: 3132-3138
12. Rijneveld AW, Weijer S, Bresser P, et al: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34:1725-1730
13. Dessing MC, Knapp S, Florquin S, et al: CD14 facilitates invasive respiratory tract infection by Streptococcus pneumoniae. Am J Respir Crit Care Med 2007; 175:604-611
14. Lichtman SN, Wang J, Hummel B, et al: A rat model of ileal pouch-rectal anastomosis. Inflamm Bowel Dis 1998; 4:187-195
15. Wan CP, Park CS, Lau BH: A rapid and simple microfluorometric phagocytosis assay. J Immunol Methods 1993; 162:1-7
16. Knapp S, Matt U, Leitinger N, et al: Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo. J Immunol 2007; 178:993-1001
17. Blander JM, Medzhitov R: Regulation of phagosome maturation by signals from tolllike receptors. Science 2004; 304:1014-1018
18. Hammerschmidt S, Wolff S, Hocke A, et al: Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect Immun 2005; 73: 4653-4667
19. Wayman NS, Hattori Y, McDonald MC, et al: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002; 16:1027-1040
20. Slomiany BL, Slomiany A: Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor gamma activation. IUBMB Life 2002; 53: 303-308
21. van Westerloo DJ, Florquin S, de Boer AM, et al: Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 2005; 166:721-728
22. Cuzzocrea S, Pisano B, Dugo L, et al: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004; 483:79-93
23. Cuzzocrea S, Pisano B, Dugo L, et al: Rosiglitazone, a ligand of the peroxisome prolif-erator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2004; 32:457-466
24. Inoue K, Takano H, Yanagisawa R, et al: Effect of 15-deoxy-delta 12,14-prostaglandin J2 on acute lung injury induced by lipopoly-saccharide in mice. Eur J Pharmacol 2003; 481:261-269
25. Rijneveld AW, Florquin S, Branger J, et al: TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 2001; 167:5240-5246
26. Asada K, Sasaki S, Suda T, et al: Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 2004; 169:195-200
27. Zingarelli B, Sheehan M, Hake PW, et al: Peroxisome proliferator activator receptorgamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003; 171:6827-6837
28. Bone RC: Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680-687